Mainz Biomed (NASDAQ:QUCY) Releases Earnings Results

Mainz Biomed (NASDAQ:QUCY) posted its quarterly earnings results on Friday. The company reported ($0.21) earnings per share (EPS) for the quarter, Zacks reports.

Mainz Biomed Trading Up 15.3%

Shares of QUCY traded up $0.46 during trading hours on Friday, reaching $3.46. The stock had a trading volume of 81,650,607 shares, compared to its average volume of 41,098,360. Mainz Biomed has a 12 month low of $0.30 and a 12 month high of $4.93. The stock’s 50-day moving average is $0.63. The company has a debt-to-equity ratio of 1.55, a current ratio of 0.50 and a quick ratio of 0.44. The firm has a market cap of $43.30 million, a P/E ratio of -0.05 and a beta of 0.42.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Weiss Ratings upgraded Mainz Biomed from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday. Maxim Group cut Mainz Biomed from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Mainz Biomed presently has an average rating of “Reduce”.

More Mainz Biomed News

Here are the key news stories impacting Mainz Biomed this week:

• Positive Sentiment: The company launched quantum-cyber.ai, a new web platform aimed at homeland security, autonomous drones, counter-UAS, EMP shielding, autonomous demining, and quantum technology applications, giving investors a clearer story around its pivot into defense-related markets. Article Title
• Positive Sentiment: A second release highlighted the same platform launch and emphasized the company’s “AI-powered, quantum-accelerated” autonomous defense positioning, which may be fueling speculative interest in the stock. Article Title
• Positive Sentiment: The company announced that former Trump administration VA Secretary Peter O’Rourke Sr. joined its board, adding a politically connected defense/government figure that could improve credibility with investors. Article Title
• Positive Sentiment: One report said the stock “rockets” on an exclusive drone technology licensing agreement, suggesting traders are reacting to a potentially meaningful commercialization catalyst. Article Title
• Neutral Sentiment: Shares were repeatedly halted for LULD pauses, indicating extreme intraday volatility and heavy trading interest rather than a standalone fundamental update.

About Mainz Biomed

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.